Skip to main content

Table 1 Baseline characteristics of HIV patients who initiated ART between 2010 and 2018 in Guangxi, China

From: Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study

Variable Total % HIV only % HIV-HBV co-infection % HIV-HCV co-infection % HIV-HBV-HCV Triple infection %
Total 58,239 100.0 46,847 100 6,707 100.0 3,828 100.0 857 100.0
Age, years
 18–50 34,424 59.1 25,731 54.9 4,504 67.2 3,404 88.9 785 91.6
   ≥ 50 23,815 40.9 21,116 45.1 2,203 32.8 424 11.1 72 8.4
Sex
 Male 39,754 68.3 31,097 66.4 4,798 71.5 3,110 81.2 749 87.4
 Female 18,485 31.7 15,750 33.6 1,909 28.5 718 18.8 108 12.6
Marital status
 Married 37,104 63.7 30,197 64.5 4,306 64.2 2,136 55.8 465 54.3
 Other 21,135 36.3 16,650 35.5 2,401 35.8 1,692 44.2 392 45.7
Route of HIV transmission
 Heterosexual intercourse 50,836 87.3 42,911 91.6 6,118 91.2 1,480 38.7 327 38.2
 Homosexual intercourse 3,455 5.9 534 1.1 152 2.3 2,257 59.0 512 59.7
 Intravenous drug use 2,827 4.9 2,488 5.3 297 4.4 36 0.9 6 0.7
 Other 1,121 1.9 914 2.0 140 2.1 55 1.4 12 1.4
CD4 count before ART, cells/mm3
  ≤ 350 34,837 59.8 28,133 60.1 3,853 57.4 2,345 61.3 506 59.0
  > 350 23,402 40.2 18,714 39.9 2,854 42.6 1,483 38.7 351 41.0
WHO clinical stage before ART 47,524 81.6 38,079 81.3 5,513 82.2 3,187 83.3 745 86.9
 I/II 7,268 12.5 5,937 12.7 807 12.0 443 11.6 81 9.5
 III/IV 3,447 5.9 2,831 6.0 387 5.8 198 5.2 31 3.6
Initial first-line ART regimen
 ART containing D4T 4,966 8.5 4,011 8.6 412 6.1 430 11.2 113 13.2
 ART containing AZT 19,621 33.7 17,208 36.7 1,027 15.3 1,176 30.7 210 24.5
 ART containing TDF 27,246 46.8 20,270 43.3 4,634 69.1 1,881 49.1 461 53.8
 ART containing LPV/r 5,863 10.1 4,862 10.4 610 9.1 319 8.3 72 8.4
 Other 543 0.9 496 1.1 24 0.4 22 0.6 1 0.1
Current ART regimen
 First-line ART 45,854 78.7 36,743 78.4 5,311 79.2 3,107 81.2 693 80.9
 Second-line ART 12,385 21.3 10,104 21.6 1,396 20.8 721 18.8 164 19.1
Duration of TDF -containing regimens
  ≤ 2 years 33,115 56.9 27,865 59.5 2,740 40.9 2,088 54.5 422 49.2
   > 2 years 25,124 43.1 18,982 40.5 3,967 59.1 1,740 45.4 435 50.8
Calendar year of ART initiation
 2010 3,515 6.0 2,518 5.4 437 6.5 425 11.1 135 15.8
 2011 4,982 8.6 3,839 8.2 604 9.0 414 10.8 125 14.6
 2012 6,226 10.7 4,876 10.4 700 10.4 537 14.0 113 13.2
 2013 6,384 11.0 5,057 10.8 738 11.0 487 12.7 102 11.9
 2014 7,290 12.5 5,755 12.3 883 13.2 558 14.6 94 11.0
 2015 8,016 13.8 6,524 13.9 954 14.2 450 11.8 88 10.3
 2016 7,421 12.7 6,170 13.2 823 12.3 349 9.1 79 9.2
 2017 7,164 12.3 5,954 12.7 830 12.4 315 8.2 65 7.6
 2018 7,241 12.4 6,154 13.1 738 11.0 293 7.7 56 6.4
  1. ART, Antiretroviral therapy; AZT, Zidovudine; D4T, Stavudine; LPV/r, Lopinavir-ritonavir; TDF, Tenofovir; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HIV, Human immunodeficiency virus
Back to article page

Infectious Diseases of Poverty

ISSN: 2049-9957

Contact us